Lantheus Holdings, Inc. (LNTH) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Bedford, MA, United States. El CEO actual es Mary Anne Heino.
LNTH tiene fecha de IPO 2015-06-25, 808 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $5.39B.
Lantheus Holdings, Inc. is a diagnostic and therapeutic company that develops, manufactures, and commercializes imaging and treatment products for heart disease, cancer, and other conditions worldwide. The company offers a comprehensive portfolio including DEFINITY for cardiac ultrasound enhancement, nuclear medicine generators and radiopharmaceuticals for diagnostic imaging, and therapeutic agents such as AZEDRA for radiotherapy and PYLARIFY for prostate cancer detection. Lantheus also markets RELISTOR for opioid-induced constipation and maintains a pipeline of investigational products including flurpiridaz F-18 for cardiac blood flow assessment and PSMA-targeted radiotherapeutics. The company serves hospitals, clinics, integrated delivery networks, and radio pharmacies through strategic partnerships with leading healthcare and pharmaceutical companies including GE Healthcare, Bayer, and Regeneron Pharmaceuticals. Founded in 1956 and headquartered in North Billerica, Massachusetts, Lantheus is a established player in nuclear medicine and molecular imaging.
